Portal vein thrombosis (PVT) is a common complication in cirrhosis, and when complete, it increases morbidity and mortality in liver transplant candidates. The aim of the study was to assess the hemostatic status, as well as clinical characteristics of thrombus and patients, as predictors of therapeutic efficacy of anticoagulation for the treatment of PVT in cirrhotics.
Patients with cirrhosis consecutively treated for PVT with enoxaparin were enrolled. All patients underwent evaluation of coagulation status and thrombophilia screening. Thrombus characteristics and extension were evaluated at baseline and during follow-up. Anticoagulation was continued until recanalization or up to 12 months. Variables correlated with the response to anticoagulation were used to create a predictive score that was validated in an external multicenter cohort.
A total of 65 patients were included and had partial PVT in most cases (72%). Treatment with enoxaparin resulted in an overall response rate of 66% (43/65) after a median time of 4.4 months and 76% (33/43) within the first 6 months. At multivariate analysis, efficacy of anticoagulation correlated with the severity of liver disease, complete verus partial PVT, age of the thrombus, and time interval from treatment start (<6 months). The areas under the curve of the statistical model for predicting the response to anticoagulation were 0.84 and 0.76 for the training (n=65) and validation (n=60) cohorts, respectively.
Early diagnosis and early treatment are key factors for the successful management of PVT in cirrhosis, so that screening of PVT and prompt start of anticoagulant treatment should be mandatory.
Departments of aSurgery, Oncology and Gastroenterology, Multivisceral Transplant Unit
bSurgery, Oncology and Gastroenterology, Hepatobiliary Surgery and Liver Transplantation Unit
dClinical Medicine I, Department of Medicine, Padua University Hospital, Padua
eDepartment of Digestive Diseases and Internal Medicine, Division of Internal Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
fDepartment of Liver Diseases and Digestive Interventional Radiology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China
Correspondence to Marco Senzolo, MD, PhD, Department of Surgery, Oncology and Gastroenterology, Multivisceral Transplant Unit, Padua University Hospital, Via Giustiniani 2, 35128, Padua, ItalyTel: +86 39 049 821 8726; fax: +86 39 049 821 8727; e-mail: email@example.com
Received February 7, 2018
Accepted April 26, 2018